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randomized, placebo-controlled, parallel-group study
was conducted in 280 patients with advanced PD who
were receiving levodopa. The study included a 7-week
escalation phase, a 4-week maintenance phase, and a 1-
week taper phase. QoL outcomes for the intent-to-treat
groups were evaluated as secondary endpoints within the
clinical trial. These endpoints were assessed through the
use of 3 fully validated QoL instruments: the PD Ques-
tionnaire (PDQ-39), the EuroQol (EQ-5D), and the Func-
tional Status Questionnaire (FSQ). RESULTS: Signiﬁcant
differences in mean change scores favoring sumanirole
were apparent in the domain pertaining to Activities of
Daily Living (ADL) within the PDQ-39 and in the Overall
Summary Score of the PDQ-39 (P < 0.0006 and P <
0.0093, respectively). Signiﬁcant differences favoring
sumanirole were observed in the domain associated with
Usual Activities in the EQ-5D (P < 0.0280) and in the
Basic Activities of Daily Living domain of the FSQ (P <
0.0092). Changes in the Mobility domain in the PDQ-39
also trended toward signiﬁcance in favor of sumanirole
(P < 0.0556). CONCLUSIONS: These data demonstrate
consistent ﬁndings of improved QoL when assessed by
each of three QoL instruments for patients with advanced
PD who were treated with sumanirole.
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Attention deﬁcit hyperactivity disorder (ADHD) is a
behavioral disorder originating in early childhood, with
a high risk for continued symptoms into adolescences and
adulthood. Although stimulant medications are often 
recommended to treat ADHD, parents’ views of these
medications have not been reported in the literature.
OBJECTIVES: To report pilot study results of a ques-
tionnaire developed to evaluate parent perceptions of
medications to treat ADHD symptoms in children.
METHODS: A parent questionnaire (Parent Perceptions
of Medication for ADHD Questionnaire) was adapted
from previously developed physician perception survey.
Prior to administration, two physicians experienced in
treating ADHD children reviewed the parent question-
naire for face validity. Item responses were either yes/no
questions or rated on a 6-point scale. Face-to-face inter-
viewer administered follow-up questions were performed
to assess questionnaire clarity and relevance. The study
subjects were recruited from a sample of parents who had
an ADHD child enrolled in a Midwestern ADHD clinic.
RESULTS: Forty-three parents of children with ADHD
participated in the study. The Flesch-Kincaid grade level
readability of the questionnaire was 3.7. A majority
(95%) of parents indicated they understood the classiﬁ-
cation of medications as a stimulant or a controlled sub-
stance however, many of the parents were not able to cor-
rectly deﬁne these terms. When deciding whether or not
to have their child take medication for ADHD, 54% and
61% stated that their decision was not inﬂuenced by
whether the medication was a stimulant or controlled
substance, respectively. A majority of the parents sur-
veyed indicated that they were concerned about their
child taking a stimulant (58%) and would prefer a non-
stimulant option if approved by the FDA (79%). CON-
CLUSIONS: Although parents reported the questionnaire
was clear and understandable, many were not able to
deﬁne key terms. With this questionnaire it was possible
to quantify parent’s perceptions towards ADHD drug
treatment.
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OBJECTIVES: To study the inﬂuence of different factors
on QOL of patients with partial epilepsy. METHODS:
Frequency, severity (NHS3 scale, M. F. O’Donoghue et
al., 1996) of seizures and QOL (QOLIE-31 scale, J.
Cramer 1998) were analyzed in the population of 242
adult epilepsy patients with partial epilepsy in Moscow.
The cross-cultural adaptation of the QOLIE-31 scale was
performed. RESULTS: Patients with partial epilepsy 
who experienced persistent seizures and received ineffec-
tive antiepileptic medication had signiﬁcantly lower total
QOL scores than patients receiving optimized therapy:
42.13 ± 4.14 and 48.89 ± 5.45, respectively (ð < 0.001).
The QOL of patients with partial epilepsy depends on 
the duration of the disease and severity and frequency 
of seizures. The severity of seizures has the strongest 
correlation with subscales of emotional well-being,
energy/fatigue, medication effects, and social functioning,
whereas the frequency of seizures had the strongest 
correlation with seizure worry, energy/fatigue, cognitive
functioning, and social functioning. After optimized
therapy 59% of patients became seizure-free. The QOL
of patients receiving optimized therapy depends on their
response to the antiepileptic medication. Seizure-free were
characterized by improvement in all subscales of QOLIE-
31, with a total score of 52.71 ± 3.41. Clinical efﬁ-
cacy/tolerability, QOL improvement, cost-effectiveness
parameters were similar on carbamazepine or valproate
monotherapy, that supports the use of valproate as ade-
quate ﬁrst-line drugs in patients with partial epilepsy.
Even one or two persistent seizures per year signiﬁcantly
decreased the patient’s QOL in comparison to seizure-free
patients. CONCLUSIONS: The quality of life of patients
with partial epilepsy depends on the duration of the
disease and severity and frequency of seizures. Long-term
ineffective therapy caused a negative effect on QOL.
